Strain Name | C57BL/6N-Tg(RP11-634C1)1(CH17-401N15)1/Bcgen | Common Name | B-Tg(hLILRB2/hLILRB3/hLILRB1/hLILRB4) mice |
Background | C57BL/6N | Catalog number | 112332 |
Related Genes |
LILRB2: ILT4, LIR2, CD85D, ILT-4, LIR-2, MIR10, MIR-10 LILRB3: HL9, ILT5, LIR3, PIRB, CD85A, ILT-5, LIR-3, PIR-B, LILRA6 LILRB1: ILT2, LIR1, MIR7, PIRB, CD85J, ILT-2, LIR-1, MIR-7, PIR-B LILRB4: ILT3, LIR5, CD85K, ILT-3, LIR-5 |
LILRB2 expression analysis in B-Tg(hLILRB2/hLILRB3/hLILRB1/hLILRB4) mice (non-tumor bearing)
Protein expression analysis
Protein expression analysis
LILRB4 expression analysis in B-Tg(hLILRB2/hLILRB3/hLILRB1/hLILRB4) mice (non-tumor bearing)
Analysis of leukocytes cell subpopulation in B-Tg(hLILRB2/hLILRB3/hLILRB1/hLILRB4) mice (non-tumor bearing)
LILRB1, LILRB2, LILRB3 and LILRB4 expression analysis in different organs of B-Tg(hLILRB2/hLILRB3/hLILRB1/hLILRB4) mice
hLILRB1 expression in CD45+ cells
Antitumor activity of anti-HLA-G antibodies (provided by a client) in B-Tg(hLILRB2/hLILRB3/hLILRB1/hLILRB4) mice. (A) Anti-human HLA-G antibodies inhibited MC38 tumor growth in B-Tg(hLILRB2/hLILRB3/hLILRB1/hLILRB4) mice. Murine colon cancer B-hB2M/HLA-G MC38 cells (5×105) were subcutaneously implanted into B-Tg(hLILRB2/hLILRB3/hLILRB1/hLILRB4) mice (female, 6-7 weeks old). Tumor-bearing animals were randomly enrolled into four study groups when the mean tumor size reached 79 mm3, at which time they were intraperitoneally injected with anti-HLA-G antibodies (provided by a client) indicated in the panel. (B) Body weight changes during treatment. As shown in panel A, the anti-HLA-G antibodies were efficacious in controlling tumor growth in B-Tg(hLILRB2/hLILRB3/hLILRB1/hLILRB4) mice, with TGITV of 33.8%, 25.1% and 37.1%, respectively. Values are expressed as mean ± SEM.